About Bacterial Vaginosis Drugs
BV is a vaginal disease caused due to complex alteration of flora present in the vagina. Antibacterial drugs are used for the treatment of BV, some of the most common drugs used for the treatment of the disease include Metronidazole, Clindamycin, and Tinidazole. The drugs are used in both oral and topical forms. Two types of bacteria are found in the genital parts of the women, termed as good bacteria and bad bacteria. The good bacteria present in the vagina are lactobacilli, which prevents the growth of bad bacteria.
Technavio’s analysts forecast the global bacterial vaginosis drugs market to grow at a CAGR of 2.16% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global bacterial vaginosis drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Bacterial Vaginosis Drugs Market 2017-2021
Technavio recognizes the following companies as the key players in the global bacterial vaginosis drugs market: Bayer, Pfizer, Sanofi, and Starpharma Holdings.
Other Prominent Vendors in the market are: Allergan, AstraZeneca, Cardinal Health, Mylan, Novartis, Sun Pharmaceutical Industries, Symbiomix Therapeutics, and Teva Pharmaceutical Industries.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is growing awareness about controlled use of antibiotics. Antibiotic resistance is one of the major problems being faced by the medical world today. It is a condition wherein an microorganism changes itself and remains no longer sensitive to that particular antibiotic. Thus, the antibiotic will no longer be capable of killing or inhibiting the growth of bacteria.”
According to the report, one driver in the market is unmet demand in BV treatment market. Unmet demand in the treatment of BV has created great opportunity for the market players. There is huge unmet need in the treatment of BV, especially the recurrent form of the disease. BV is the most common vaginal infection in the women of child bearing age group. Despite being highly prevalent in nature, little has been done in the field. When left untreated, it may lead to severe infections, especially in the case of pregnant women such as preterm births.
Further, the report states that one challenge in the market is development of resistance against antibiotics. The development of multidrug-resistant microbes is one of the major threats to the human health. The microbe changes itself to protect against the antimicrobial agent used and thereby develops resistance to the drug. This develops largely due to the irrational use of drugs. Incorrect prescription of the drugs by physicians or incorrect dosing or course taken by patients leads to the development of resistant drugs. This occurs because of the increased accumulation of drugs in the body. The commonly used antibiotic drugs thus become ineffective against microbes, leading to aggravation of disease in the body.
Bayer, Pfizer, Sanofi, Starpharma Holdings, Allergan, AstraZeneca, Cardinal Health, Mylan, Novartis, Sun Pharmaceutical Industries, Symbiomix Therapeutics, and Teva Pharmaceutical Industries.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook